Company withdraws application for stress incontinence drug

Eli Lilly said it has withdrawn its new drug application for duloxetine hydrochloride for the treatment of stress urinary incontinence.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria